In ten minutes a day, You too can be ON TOP of the biopharma industry
Call John D Waddell, RPh @ +1-610-952-1871
TSM Associates are…
Creative
Experienced
Committed
BioPharma Industry News
-
Baffling ban on human gene patents won't impede biotech
-
Biogen CEO under pressure for successful Tecfidera MS launch
-
bluebird bio prices $101M IPO for orphan dis gene therapies
-
Forget lab rats, microchip may be better asthma efficacy model
-
NCATS looks to avoid regs hurdles for abandoned drugs
-
NIH expects patient level data from all GLP-1 mfrs
-
Patent settlements may become much more risky
-
Pharma scrambling to create 'Sunshine' data systems by Aug 1
-
PwC projects historic slowdown in US health spending in 2014
-
Top 12 pharmas garnered just 25 of 68 NME NDAs in last 2 yrs
-
AMA votes to recognize obesity as an epidemic disease
-
Astellas looking to sell dermatology biz unit $500M to $1B
-
AstraZeneca turnaround is 3-4 year journey, says CEO
-
Bernard Munos on the last twelve years of pharma
-
Large indep PCP groups spend less, follow CMS guidelines
-
Medivation's been trying to block J&J's newly acquired ARN-509
-
MRI may be warranted for potential contaminated steroid infection
-
Pharma-backed studies more prominent at Ca meetings
-
PharmaFutures investor thinktank: Biz model overhaul needed
-
UCLA presents Medicinova's MN-166 Ph 1b in meth addiction
-
US appeals court rules Novo Nordisk PrandiMet patent invalid
-
10 takeaways from FDA's 2013 warning & untitled letters
-
A forensic analysis of drug targets from 2000 through 2012
-
Adamas' ADS-5102 wins in Ph 2/3 for Parkinson's dyskinesia
-
Analysts: GSK's Votrient will overtake Pfizer's Sutent in 2016
-
Biotech reps make an average $165K in annual compensation
-
FDA proposes more transparent approval apps, de-ID pat data
-
FDA studying 2 deaths of patients on Lilly's long-acting Zyprexa
-
Supreme Court tells drug makers & FTC to go to war
-
Takeda launches Nesina, Kazano & Oseni GLP-1 prods in US
-
UK website sells unlicensed polypill for heart attack prevention
-
ViroPharma says it's not looking but rumors are circulating
-
BCG: Best to be 1st vs best-in-class; Trout & Reis said so in 1994
-
Didn't take long: Pathway Genomics to offer BRCA test
-
GSK negotiating $1B sale of Arixtra & Fraxiparine to Aspen
-
NYC warns of meningitis outbreak in prep for gay pride events
-
Questcor paid $165M to block Retrophin threat to Acthar Gel
-
Royalty Pharma withdraws appeal; $8B bid for Elan expires
-
Santarus/Pharming: FDA accepts Ruconest BLA in acute HAE
-
Sorry agencies but lack of ROI is social-media's real dilemma
-
Standard & Poor's cuts Endo Health further into junk territory
-
Valeant Pharma to launch $9.3B Bausch acquisition financing
-
XO1 wins VC for ichorcumab, bleed-free mAB anticoagulant
-
"Real risk" for Novo's Victoza from Lilly's dulaglutide; Shrs fall
-
Angel investors are starting to look a lot like VC's
-
AstraZeneca and NGM in EEC hormone obesity & diabetes deal
-
AstraZeneca picks site for new global HQ in Cambridge, UK
-
Citing side effects, Japan withdraws recs for HPV vaccines
-
Congress presses DEA to open up on regulatory 'black hole'
-
Dana-Farber: More evidence for wait-&-see in prostate Ca
-
Elan investors clear buy back in blow to Royalty Pharma
-
IARC: Blood tests may detect sexually-transmitted oral Ca's
-
J&J pays up to $1B to acquire Aragon & androgen blkr program
-
Lilly pays $7/240M for Transition's GLP-1, TT-401 on Ph 1b data
-
Novartis' health educators represent a sound strategy in China
-
Onconova files $75M IPO for small anti-Ca mol(s) in hot mrkt
-
Savara: Angels give $16M for AeroVanc Ph 2b in CF/MRSA
-
Supreme Court: 'Pay-to-delay' deals can violate antitrust law
-
Teva acquires MicroDose Therapeutx, resp drug delivery firm
-
10 takeaways from FDA's 2013 warning & untitled letters
-
Alnylam's Ph 2 for ALN-TTR02 has brought $300M into RNAi
-
As patent cliff's end nears, generic mfrs look to sell brands
-
FBI: Chicago hosp over-sedated pats to bill $160K tracheotomies
-
Given Imaging ready to launch its 3rd generation PillCam
-
HFMA: 77% of doc-hosp deals based on productivity or volume
-
Medtronic's Infuse has limited benefit, may do harm - 2 reviews
-
MIT professor's financial engineering just may 'cure cancer'
-
Myelofibrosis death risk cut 52% in Ph 3 with Incyte's Jakafi
-
Myriad RBM developing molecular tests for mental ailments
-
Repros proposes offering for Proellex-V Ph 2b in uterine fibroids
-
Timely access to NPs, PAs wins out over PCPs in AAMC study
-
Walk-in, retail clinics are gaining popularity vs PCPs
-
AbbVie's BCL-2 blkr, ABT-199/GDC-0199 OK in CLL, NHL Ph 1
-
Amgen's new drugs may drive growth beyond 2012's 43%
-
Amicus exploring options after FDA migalastat delay in Fabry
-
BMS and Simcere expand China Orencia alliance in RA
-
Hostility may be easing as Elan invites Royalty Pharma bid
-
J&J's Depuy Synthes wins $16M in patent case v. Globus Med
-
Moody's downgrades Teva on $2.2B Pfizer Protonix settlement
-
Questcor leads the pack while Dynavax tanked this week
-
Roche's Avastin approved for glioblastoma in Japan
-
Stroke risk is top oral anticoagulant driver in outpatient afib
-
Wall Street realizes Myriad monopoly is done; Downgrades rain
-
Amgen's rebuilding in Japan may speed up drug devt for all
-
Biosimilar developers seek clarity on FDA biosimilar guidance
-
Both Pfizer's Eliquis & Xeljanz are not selling as well as planned
-
Eastern Europe intros Western Europe style reimbursement
-
FDA's latest patient-focused drug devt efforts in full swing!
-
Heartbreak of Alzheimer's through the eyes of caregivers
-
Line: #1 growth social network incredibly attractive to marketers
-
Merck cuts R&D jobs 2 mos after Amgen research chief arrives
-
MRN's social intelligence beats epidemiology for trial recruiting
-
Pfizer gets chance to overturn liability for generic mfr's Reglan
-
Third Rock, with 2 IPO's in queue, not only VC growing their own
-
Verastem gets EU orphan status for VS-6063 in mesothelioma
-
WellDoc's FDA OK'd motivation, education & T2D coaching
-
'Instagram for Doctors': No more waiting to publish in journal
-
AMA to pharmacists on opioid abuse: Don't call us we'll call you
-
Cangene withdraws EMA MAA for IB1001 (rFIX) in hemophilia B
-
Conatus files for $69M IPO for emricasan in liver apoptosis
-
Depression tops dis activity & Tx response to predict disabilty
-
Elan puts itself up for sale @ nth hour to fend off hostile bid
-
England's latest Innovation Scorecard: A patchy picture
-
FDA guidance for combinations of 2 drugs that are both novel
-
Forest launches once-daily Namenda XR in US for Alzheimer's
-
Harvard Pilgrim ends coverage for compounded meds
-
Herper: For 23andMe, the real value could be in its data
-
Myriad gene patent ruling triggers race for Ca tests
-
Myriad: Praise and perils for biotechnology patent policy
-
Supreme Court gets decision right, science wrong, in Myriad
-
UK ignored Ranbaxy whistleblower at heart of GMP scandal
-
AbbVie & Eisai get Japan OK for 40mg Humira pre-filled for UC
-
AbbVie Says it can be first with all-oral hepatitis C regimens
-
Biotech focused on patentable complementary DNA anyway
-
Elan rises; Investors reject 3 of 4 proposals blocking Royalty bid
-
EU regulator advises caution on painkiller Voltaren (diclofenac)
-
FT Healthcare Conference: Society as stakeholder
-
Gleevec patent battle between Sun & Novartis shifts to US
-
GSK probes 'widespread bribery' allegations in China - WSJ
-
Lilly halts BACE inh, LY2886721 Alzheimer's Ph 2 on liver toxicity
-
Myriad's loss a win for innovation, say victors. And Myriad rises
-
Reason for optimism and angst in SCOTUS Myriad ruling
-
Two-thirds of Americans would participate in trial on doc's rec
-
Venter wins w/ integrated disciplines, synergistic conversation
-
A delay in ACA relief from copays for costly drugs
-
A single slide shows how Vertex will dominate cystic fibrosis
-
AARP fears Pfizer tactics to defend Lipitor could become model
-
Accenture: ObamaCare will bring flood of retail health clinics
-
CDC: Gilead's 'nuc', Truvada halves HIV risk in IV drug abusers
-
Digital tech enables health care cost containment strategies
-
Merck joins Novo Nordisk to reassure FDA of GLP-1 safety in T2D
-
National Pharmaceutical Council: Steady supply of CER ideas
-
Pfizer, Takeda settle Protonix patent suit v. Teva, Sun for $2.2B
-
AACE in general, is not warm & fuzzy when it comes to patients
-
Adeno-assoc virus delivers gene Tx to retina with VH inj
-
Almirall & Ironwood launch Constella for IBS-C in EU
-
AstraZeneca & Takeda bid for Israel Chief Scientist's incubator
-
AstraZeneca taps academia to screen cancer compounds
-
Biogen falls on concerns over Tecfidera EU regs data protection
-
Brain PET scans allow 1 day antidepressant response assessment
-
CDC: Flu season doc visits reached record with early peak
-
Divisive Elan boss Martin faces ownership showdown
-
Elan drops as Royal Pharma says takeover may fail
-
FDA approves Amgen's Xgeva for giant cell tumors of bone
-
G8 ministers pledge to act on bacterial antibiotic resistance
-
GSK finds no evidence of bribery in 4 month probe of China unit
-
GSK puts IL-7, GSK 2618960 on hold after China R&D fraud
-
How today's Supreme Court ruling affects the biotech industry
-
Human genes cannot be patented; Myriad's methods not novel
-
J&J sells final stake in Elan for $332M; Not mtl to Royalty bid
-
Lilly sponsoring MDLinx oncology journal aggregator for a year
-
Lilly's JAK inh, baricitinib effective in 52-week Ph 2 for RA
-
Men with restless legs tied to 30% greater death risk over 8 yrs
-
Mixed Supreme Court ruling on BRCA1, breast Ca mutation
-
MM&M's healthcare marketing awards finalists announced
-
NYT: Healthcare is a very local & very brutal business
-
Orphagen aims to discover orphan nuclear receptor regulators
-
Prism gets $15M ser C for PRI-724 in non-oncology indications
-
Public Health England launches world's largest Ca pats d'base
-
Ranbaxy plans 3-4 ANDA's per year with 6-month exclusivity
-
Reuters inadvertently published embargoed HIV story
-
SALL4 gene is biomarker for aggressive subtype of liver Ca
-
SEC accuses brothers of insider trading in Sanofi/Chattem deal
-
Sequestration's uniform Medicare cut to yield disparate impacts
-
Some call Battelle's human genome ROI math "ridiculous"
-
UCB's epratuzumab shows no new safety signals in lupus Ph 2b
-
Zydus/Cadila recalls one lot of oversized warfarin 2mg tabs
-
$14.5B invested in human genome project led to $966B boom
-
2nd psychiatry protest against Nemeroff in less than one year
-
A drug market wrecked by government - AEI in TB drugs
-
ABPI wants more NHS data on uptake & access to new meds
-
Active Biotech/Teva's laquinimod wins Ph 2a in lupus nephritis
-
Amgen pays Cytokinetics $75M; adds Japan to omecamtiv deal
-
Amgen's trebananib extends PFS by 1.8 mos Ph 3 for ovarian Ca
-
Benitec gets NIH RAC cmte OK to take hep C gene Tx 'into man'
-
Calista's preclinical peptides could alter course for all CF pats
-
Can seating arrangements @ FDA adv panels influence voting?
-
Celgene's apremilast wins in Ph 3 for psoriatic arthritis
-
Clovis ups pricing of public offering from $170M to $240M
-
Contract Pharma's Fourteenth Annual Salary Survey - 2013
-
CRO Outlook & Market Trends: Globalization & collaboration
-
Cut-rate concierge med: Retail clinics appeal to high-earners
-
Emory's new model for early-stage spinouts, collaborations
-
FDA building a prescription drug and marketing database
-
France's "Sunshine Act" sheds little light on pharma doc pmts
-
GlobalData: Sanofi's Fluzone QIV to be US market leader
-
GSK wins NICE rec with discount for platelet-boosting Revolade
-
Immune Design, NY non-profits team up to boost Ca drugs
-
Indian drug regulator may order inspection of Wockhardt mfrg
-
Medicare Part D plans use 2-3x more brand drugs vs VA
-
Myriad case headline will be, 'Human genes are not patentable'
-
NICE recs Thrombogenics' Jetrea in vitreomacular adhesion
-
Nuron CEO is "under construction" with no replacement
-
Oncology spend constant at under 5% of total spend over 20 yrs
-
PDL files for arbitration vs Roche in royalty underpayment case
-
Puma opens Ph 3 for neratinib in HER2+ metastatic breast Ca
-
QRxPharma gets US composition patent for hybrid opioids
-
Questcor surges after acquiring rights to Novartis' Synacthen
-
Royalty pursuing hostile bid for Elan, fights Irish panel ruling
-
Royalty says Elan mislead its shareholders over vote
-
Surviving childhood Ca leads to adult chronic CV, resp illness
-
Teva pacakaging error may be case of malicious tampering
-
US Fish & Wildlife Service proposes end to chimp use in R&D
-
VA: Amgen's Enbrel no better than generic cocktail in RA
-
Vertex has a roadmap to $10B in cystic fibrosis drug sales
-
Walgreens in record-setting $80M DEA opiod settlement
-
When it comes to CV diagnostis, culture even trumps evidence
-
'Social entrepreneurship' is usually cliche; Not w/ Uganda's QCI
-
30% of execs expect blockbuster model to continue as norm
-
Abbott tripled Niaspan use in 7-year prior to 2011 trial flop
-
Agios files for $86M IPO for Ca & inborn metabolism devt
-
Ampio blames shorts but won't answer legitimate questions
-
AstraZeneca buys Pearl & LABA/LAMA, PT003 for up to $1.15B
-
Baxter warned of presence of mold in sterile mfrg process
-
Biogen Idec raises FY 2013 guidance; Sales up by over $1B
-
BioLineRx licenses BL-8030 to Jiangsu CTTQ in hep C
-
BMJ: Has pancreatic damage from GLP-1s been underplayed?
-
CardioNet umps on UHC reimbursement for heart-monitors
-
Cigna signs 10-year deal with Canadian PBM, Catamaran
-
CT scan overuse in kids may trigger 5K US Ca's per year
-
Debt-ridden Elder Pharma of India is up for sale
-
Dermira scores $35M ser A for dermatology pipeline
-
Elan voluntarily dismisses US lawsuit against Royalty Pharma
-
EMA guidance fails to define similarity threshold for biosims
-
Ex-MedImmune CEO installed at Histogenics, regenerative med
-
FDA adds 18 pathogens to antibiotic devt incentives list
-
FDA wants to make 'masked' trial data open to outside experts
-
Five best-performing biopharma stocks of 2013.. Surprises
-
Forest adds Icahn director in pact to avoid proxy fight
-
Former BMS exec admits, pleads guilty to insider trading
-
Four Philly-area deals last week: Three start & one ends badly
-
GenSpera patents prostate Ca peptide, HK2-activated prodrugs
-
Global Alzheimer's mrkt to decline as unmet need soars
-
Health Canada denies Novartis' Lamprene for dying patients
-
Japan is 3rd-country to get expemption to ship APIs to the EU
-
Medikly, social media mktg platform to recruit investigators
-
Novartis India probes sales practices for Galvus; Heads roll
-
Pearl deal gives AstraZeneca hold in emerging LABA/LAMA mrkt
-
Roche gets Swiss approval for Erivedge, 1st for basal cell Ca
-
Sanofi joins GSK, MedImmune w/ 4-in-1 flu vax, Fluzone Quad
-
Sanofi's Lemtrada near MS approval after 25 year devt saga
-
Senators urge swift vote on drug compounding bill
-
Shire's new CEO adds sales staff, damps takeover talk
-
Tax leverage helps make Irish pharma a popular target
-
WHO: MERS coronavirus has potential for flu pandemic
-
Will Scotland take a different approach to value-based pricing?
-
Activist investor sends Alere letter calling for unit sales
-
Almac plans to add 200 manufacturing jobs in Ireland
-
AMAG gets US rights to Adamas' MuGard in oral mucositis
-
Apricus Biosciences gets approval for Vitaros,topical alprostadil in 10 EU countries
-
Arc protein lacking in Alzheimer's patients, a factor in autism
-
Array presents interim data for ARRY-520 & biomarker in myeloma
-
Avaxia gets $11.4M ser B for anti-TNF drugs active only in GI
-
Biggest winner from Avandia's resurrection at FDA: Teva
-
Biocon CEO: Ranbaxy issue a wake up call for Indian pharma
-
Biotech is long-term biz, in a short-term thinking world - Sarepta
-
Catalent expands in Kentucky and plans to add 90 jobs
-
Celebrity Russian spy wants to transform its biotech biz
-
Clinical Trial Ca Mission 2020 Act enforces registry data banks
-
Clovis nearly doubled last week; Synta took a big dive
-
Daiichi Sankyo launches Pralia in Japan for osteoporosis @ $293/mon
-
Elan claims rival approaches, holds out for $15.50 per share
-
Extended-release amantadine shows promise in Parkinson's
-
FDA accepts RedHill/IntelGenz' NDA for RHB-103 oral rizatriptan in migraine
-
FDA asks for more safety data on Dynavax' Heplisav, hep B vax
-
FDA finalizes Oct 2011 changes to orphan drug regulation
-
FDA issues CGMP warning letter to Novartis on Austria plant
-
FDA rejects Aveo's tivozanib in kidney Ca, asks for addl trial
-
FDA scraps IND's for fecal transplants, developing guidance
-
FDA's OPDP warns J&J for misbranding Doxil on website
-
France probes fatal med error after ANSM orders Teva recall
-
Geneticists push for global data-sharing - Nature
-
Gilead's idelalisib shows response in Ph 2 for refractory indolent non-Hodgkin's lymphoma
-
Hope nobody paid for the 39 patient 'trial' published in JAMA
-
Indian chain, Apollo resumes selling Ranbaxy drugs
-
Investors warn WPP's Sorrell, he's in "last chance saloon"
-
J&J seeks home NJ court advantage in Tylenol damage suits
-
John Waddell, RPh of TSM will be speaking at MICHBIO on 'Commercial Opportunity Assessment & Go-To-Market Strategies' on Fri, June 21 at The University of Michigan Research Complex
-
Licensing deals: Difference between 'in biz' & 'closing shop'
-
Lower costs of sequencing don't matter if silos prevent sharing
-
Medivo gets $15M to expand consumer lab data access efforts
-
Mylan Inc: A financial and strategic SWOT analysis review
-
NanoViricides files DengueCide orphan app for dengue fever
-
Outlier hospitals may cherry-pick PCI patients for reporting
-
Patheon returns to profit with boost from Latin America
-
Pfizer/Takeda launch Enbrel subQ autoinjector in Japan for RA @ $293
-
Richter licenses Esmya to HRA Pharma for uterine myoma in Latin America
-
Rocephin/Zithromax combo slows Suprax gonorrhea resistance
-
Roche gets EU nod for RoActemra in pediatric RA
-
Royalty Pharma urges US federal court to let Elan bid proceed
-
Stemline gets orphan designation for SL-401 in BPDCN
-
Supernus gets tentative FDA approval Trokendi XR (topiramate)
-
Supreme Court ruling expected any day on Solvay pay-to-delay
-
Swedish Orphan Biovitrum gets FDA OK to mfr Kineret API with Boehringer Ingelheim
-
UCB to partner with crelux and 4sc for neurology research
-
US Supreme Court: 'Pay for delay' lawsuits can continue
-
US Supreme Court: FTC can challenge 'pay to delay' deals
-
Valent backs out of bid for Serbia's Galenika Pharmaceuticals
-
ViroPharma gets orphan designation for Maribavir in EU
